Who was studied?
One older patient with refractory metastatic hepatoid adenocarcinoma of the stomach.
What does the publication report?
Tumor shrinkage followed by a pathological complete response was reported.
Safety findings
Mild abdominal pain was described; no serious adverse events were reported in the abstract.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer · DOI: 10.3389/fonc.2025.1726271 · PMID: 41626177
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.